The stock's rise snapped a four-day losing streak.

BMO Capital analyst Daniel Jester lowered the firm’s price target on Vertex (VERX) to $41 from $56 and keeps a Market Perform rating on the ...

DA Davidson analyst William Jellison lowered the firm’s price target on Vertex (VERX) to $55 from $62 and keeps a Buy rating on the shares.

We recently compiled a list of the 10 Stocks Drop by Double Digits Mostly Due to Disappointing Earnings. In this article, we ...

Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeuti | Vertex has backed out of its in vivo ...

KING OF PRUSSIA, Pa. — KING OF PRUSSIA, Pa. — Vertex, Inc. (VERX) on Thursday reported a loss of $67.8 million in its fourth quarter. On a per-share basis, the King Of Prussia, Pennsylvania-based ...

Vertex Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, today announced the ...

Arc’teryx has introduced four new technical models to its footwear roster: Norvan LD 4, Vertex Speed, Norvan Nivalis, Konseal ...

The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...

Arc'teryx’s new footwear models will be available globally, launching throughout 2025. The Norvan LD 4 arrives in March, ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

Vertex Pharmaceuticals (NASDAQ:VRTX) announced Friday that an expert panel of the EU drug regulator, the European Medicines ...